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Abstract
Background: Ciliary neurotrophic factor (CNTF) has been regarded as a potent trophic factor
for motor neurons. However, recent studies have shown that CNTF exerts effects on glial cells as
well as neurons. For instance, CNTF stimulates astrocytes to secrete FGF-2 and rat microglia to
secrete glial cell line-derived neurotrophic factor (GDNF), which suggest that CNTF exerts effects
on astrocytes and microglia to promote motor neuron survival indirectly. As CNTF is structurally
related to IL-6, which can stimulate immune functions of microglia, we hypothesized that CNTF
might exert similar effects.
Methods: We performed 2-D and 1-D proteomic experiments with western blotting and flow
cytometry to examine effects of CNTF on primary microglia derived from neonatal mouse brains.
Results: We show that murine microglia express CNTF receptor α (CNTFRα), which can be
induced by interferon-γ (IFNγ). Whereas IL-6 activated STAT-3 and ERK phosphorylation, CNTF
did not activate these pathways, nor did CNTF increase p38 MAP kinase phosphorylation. Using 2-
D western blot analysis, we demonstrate that CNTF induced the dephosphorylation of a set of
proteins and phosphorylation of a different set. Two proteins that were phosphorylated upon
CNTF treatment were the LYN substrate-1 and β-tubulin 5. CNTF weakly stimulated microglia,
whereas a stronger response was obtained by adding exogenous soluble CNTFRα (sCNTFRα) as
has been observed for IL-6. When used in combination, CNTF and sCNTFRα collaborated with
IFNγ to increase microglial surface expression of CD40 and this effect was quite pronounced when
the microglia were differentiated towards dendritic-like cells. CNTF/sCNTFRα complex, however,
failed to increase MHC class II expression beyond that induced by IFNγ. The combination of CNTF
and sCNTFRα, but not CNTF alone, enhanced microglial Cox-2 protein expression and PGE2
secretion (although CNTF was 30 times less potent than LPS). Surprisingly, Cox-2 production was
enhanced 2-fold, rather than being inhibited, upon addition of a gp130 blocking antibody.
Conclusion: Our studies indicate that CNTF can activate microglia and dendritic-like microglia
similar to IL-6; however, unlike IL-6, CNTF does not stimulate the expected signaling pathways in
microglia, nor does it appear to require gp130.
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Background
Microglia are the resident immune cells of the CNS and
they exert innate and adaptive immune functions like
peripheral macrophages. Normally microglia display a
ramified morphology and they act as support cells. When
nervous system homeostasis is disturbed by hazardous
stimuli, like viruses, bacteria or traumatic injury, micro-
glia become activated and are capable of secreting an array
of soluble factors that include cytokines, chemokines and
reactive nitrogen and oxygen species. Activated microglia
can also act as phagocytes to engulf tissue debris and dead
cells [1]. They may also become antigen presenting cells
(APCs), which present antigenic peptides mounted on
major histocompatibility complex (MHC) molecules to T
lymphocytes to stimulate a cascade of T cell responses [2-
4]. These immune properties of microglia are exquisitely
regulated by cytokines secreted from T cells. The Th1
cytokine, IFNγ can stimulate microglia to increase phago-
cytosis and expression of MHC class II and CD40 mole-
cules [5-7], whereas Th2 cytokines, like IL4 and IL-10, can
counter-act the effect of IFNγ on microglia [8,9]. Interac-
tions between T cells and microglia are important deter-
minants for the extent of inflammation in the CNS.
Multiple sclerosis (MS) is a T cell-mediated demyelinating
disease of the CNS and the expression of antigen present-
ing molecules on microglia has a pivotal role in the devel-
opment of MS. Cell-cell interactions mediated by MHC
and co-stimulatory molecules, including CD40, B7.1 and
B7.2 molecules, expressed on the microglia and T cell
receptors (TCR) and specific counter receptors for the co-
stimulatory molecules located on the surface of T cells are
essential for optimal T cell-APC adhesion and reciprocal
activation [10,11]. Studies on experimental autoimmune
encephalomyelitis (EAE), an animal model for MS, show
that microglial activation precedes the onset of disease
symptoms and the activated microglia exhibit increased
expression of MHC class II, CD40 and B7 molecules [12].
In addition, activated microglia may also express cycloox-
ygenases (Cox), which are enzymes that generate prosta-
noids. Prostanoids, including prostaglandins and
thromboxanes, are potent factors that can act on a variety
of cells and have diverse actions [13]. However, these fac-
tors are short-lived and only act in a paracrine or autocrine
manner. Cox-2 is the inducible form of Cox and it is rap-
idly expressed by microglia in response to injury. Whereas
Cox-2 expression is undetectable in microglia in healthy
subjects, there is a significant induction of Cox-2 in
chronic active MS lesions [14]. Cox-2 expression has been
identified in macrophages/microglia adjacent to damaged
oligodendrocytes, suggesting that microglial expression of
Cox-2 is involved in the development of demyelination.
The metabolites of Cox, prostaglandin D (PGD) and PGE,
are at higher concentrations in cerebrospinal fluid (CSF)
of MS patients in active disease state compared to healthy
controls [15,16]. Concentrations of PGE increase sharply
before the onset of clinical symptoms and drop during
deterioration to return to basal levels [17]. These studies
suggest that the production of Cox-2 and PGE closely cor-
relate with the development of MS.
Brain cells can also produce cytokines that modify the
extent and nature of neuroinflammatory responses. Cili-
ary neurotrophic factor (CNTF), a member of the inter-
leukin-6 family of cytokines, is produced following brain
injury by astrocytes. Named on the basis of its initially
characterized bioactivity, CNTF directly supports the sur-
vival of a variety of neuronal populations [18-24]. In addi-
tion, CNTF activates astrocytes, promoting their capacity
to support neurons and oligodendroglia [25,26]. How-
ever, the effects of CNTF on microglia have been only par-
tially studied [27-29]. Transgenic mice studies have
shown that CNTF is required to maintain motor neurons
after birth because CNTF knockout mice develop a pro-
gressive loss and atrophy of motor neurons and exhibit
reduced muscle strength in adulthood although they are
fully viable and developmentally normal [30]. Whereas
CNTF is regarded as an important injury induced
cytokine, cardiotrophin-like cytokine (CLC), which is a
structurally related factor with CNTF and binds to CNTF
receptor-α (CNTFRα) leading to activation of gp130, LIF
receptor and STAT3 [31], is developmentally important.
Similar to CNTFRα knockout mice, animals with CLC
deletion die as neonates from loss of motor neurons
affecting the facial nucleus [32].
In particular, CNTF has been shown to reduce the symp-
toms of EAE and the absence of CNTF exacerbates the
severity of MS disability. MS patients with CNTF null
mutations develop disease symptoms at earlier ages with
more severe motor disabilities and more relapses com-
pared to individuals who are CNTF heterozygotes [33].
Similar results are also seen in CNTF knockout mice
induced with EAE [34]. Whereas individuals with a CNTF
null mutation develop earlier and more severe disease,
being a CNTF null or heterozygote is not a risk factor for
developing MS. On the other hand, intravenous injections
of CNTF induce acute-phase responses in rat liver cells
with increased expression of β-fibrinogen,  α-1-antichy-
motrypsin and α-2-macroglobulin [35,36]. These effects
suggest that CNTF might regulate immune responses
within the CNS as well.
Several studies have shown that injecting CNTF directly
into the neocortex induces several features of gliosis where
astrocytes become hypertrophic with increased GFAP
expression and microglia become more ameboid
[29,37,38]. Studies on cultured rat microglial cells have
shown that CNTF can induce low-affinity nerve growthJournal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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factor receptor and CD4 expression [27], suggesting that
CNTF can exert direct effects on microglial cells. Indeed,
we have recently reported that CNTF-treated rat microglia
secreted soluble factors that increase motor neuron sur-
vival [39]. The goal of the current studies was to elucidate
how CNTF regulates the immune functions of murine
microglia.
CNTF belongs to the IL-6 cytokine family, which includes
leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1),
oncostatin-M (OSM) and IL-11. IL-6 family cytokines
share glycoprotein 130 (gp130) as a common signal trans-
ducer, and similar to other IL-6 cytokines, CNTF may also
signal through Janus Kinase (Jak)/signal transducers and
activators of transcription (STAT) and the mitogen-acti-
vated protein kinase (MAPK) pathways. The canonical
CNTF receptor is a tripartite complex composed of the
binding protein for CNTF, the CNTF receptor α (CNT-
FRα), the LIF receptor (LIFR) and gp130 [40]. CNTFRα is
linked to the cell membrane through a glycosyl phos-
phatidylinositol (GPI) linkage and like other GPI-linked
receptors it can be cleaved by phosphatidylinositol-spe-
cific phospholipase C (PI-PLC) to create a freely soluble
receptor [41]. The complex formed by sCNTFRα and
CNTF can, therefore, serve as agonists for cells that do not
express CNTFRα.
In this study, we first examined whether murine microglia
express CNTFRα. Then, we stimulated microglia with
CNTF alone or in combination with soluble CNTFRα to
determine how the CNTFRα signals. We also investigated
whether CNTF regulates antigen presenting molecules
and prostaglandins produced by microglia. Cumulatively,
our studies indicate that CNTF can activate microglia sim-
ilar to IL-6, however, unlike IL-6, CNTF does not stimulate
expected signal transduction pathways nor does CNTF
appear to require gp130 to affect microglia.
Methods
Materials
Recombinant rat CNTF (rrCNTF) was purchased from
Alomone (C-245, Jerusalem, Israel), and recombinant
mouse IL-6 (rmIL-6, 406-ML-005), recombinant mouse
IL-6 receptors (rmIL-6R, 1830-SR-025), recombinant
mouse interferon-γ (rmIFNγ, 485-MI-100) and recom-
binant mouse granulocyte-macrophage colony-stimulat-
ing factor (rmGMCSF, 415-ML-010), were purchased
from R&D Systems (Minneapolis, MN). Recombinant
mouse leukemia inhibitory factor (rmLIF, LIF2010) was
purchased from Chemicon (Temecula, CA). COX-2 anti-
body (160126, lot 155350-1) was purchased from Cay-
man Chemical (Ann Arbor, Michigan) and CNTFRα
antibody (558891) was purchased from BD Pharmingen.
β-Tubulin antibody (sc-9104) was purchased from Santa
Cruz Biotechnology, Inc (Santa Cruz, CA). STAT3 (9132),
phospho-STAT3-tyr705 (9131), phospho-ERK1/2 (9101)
and ERK1/2 (9102) antibodies were purchased from Cell
Signaling Technologies (Beverly, MA). Phospho-tyrosine/
serine/threonine antibody was purchased from AbCam
(ab15556, Cambridge, MA). Horseradish peroxidase
(HRP)-conjugated secondary antibodies were purchased
from Jackson ImmunoResearch Laboratories (West
Grove, PA).
Enriched microglial cultures
Primary mixed glial cultures were prepared from P0-2
mouse brains. Briefly, C57BL/6 mouse pups were sacri-
ficed by decapitation and the whole brains excluding cer-
ebellums and olfactory bulbs were isolated. The meninges
were removed, tissues were enzymatically digested using
Accutase (AT104, Innovative Cell Technologies, San
Diego, CA) and mechanically dissociated, and the cell sus-
pension was passed through 100 μm cell strainers and
centrifuged at 1,500 rpm for 7.5 min. Cells were counted
using a hemocytometer in the presence of 0.1% trypan
blue and plated into 75 cm2 tissue culture flasks at a den-
sity of 2 × 105 viable cells/cm2 in minimum essential
medium (MEM, 11090-99, Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, 100 U/100 μg/ml penicillin/streptomycin and
0.6% glucose (MEM-10C). Medium was changed every 3
days after plating. On day 9, the mixed glial cultures were
shaken on an orbital shaker at 250 rpm for 60–75 minutes
to dislodge microglial cells. The nonadherent cells after
shaking were plated onto 6-well or 12-well plates at 8 ×
104 viable cells/cm2, and incubated in 37°C for 30 min to
allow microglial cells to adhere. The wells were rinsed
extensively with MEM to eliminate nonadherent cells and
debris. The enriched microglial cultures were fed with 2
mL/well in 6 well plates or 1 mL/well in 12 well plates.
The medium contained MEM supplemented with 1% FBS,
0.66 mg/ml BSA, 100 μg/ml d-biotin, 5 ng/ml insulin, 1
ng/ml selenium, 40 μg/ml iron poor transferrin, 2 mM
glutamine, 15 mM HEPES buffer, and 100 U/100 μg/ml
penicillin/streptomycin (MCDM). Enriched microglia
were treated with cytokines ~18 hours after plating. Purity
of the enriched murine microglial cultures was confirmed
to be > 99% by CD11b and A2B5 staining.
Protein isolation
After cytokine treatments, microglial cells were washed
three times with PBS, then lysed in buffer containing a
final concentration of 1% Triton-X-100, 10 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 0.5% nonidet P-40, 1 mM EDTA,
0.2% EGTA, 0.2% sodium orthovanadate and 1 μL/mL
protease inhibitor cocktail (P8340-1 ML, Sigma, St. Louis,
MO). Samples were rocked at 4°C for 15 minutes. DNA
was sheared using a 21-gauge needle prior to centrifuga-
tion at 10,000 rpm for 10 min at 4°C. Protein concentra-
tions from the supernatants were determined using the
BCA colorimetric assay (Pierce, Rockford, IL). Protein
lysates were aliquoted and stored at -20°C until needed.Journal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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Enzyme-linked immunosorbent assay (ELISA)
Prostaglandin E2 (PGE2) content in the supernatant was
assayed by ELISA developed with commercially available
PGE2  ELISA kit purchased from Caymen Chemical
(514010). Cells were stimulated with rrCNTF (5 ng/mL)
and sCNTFRα (200 ng/mL) or left untreated for 18 hours.
Supernatants were collected and frozen in -20°C until
assayed.
Western blotting
Ten to fifteen micrograms of protein isolated from the
microglial cells was separated on 7% Tris-Acetate polyacr-
ylamide gels (Invitrogen), electrophoresed at 150 V for 80
minutes, and transferred at 300 mA for 80 minutes to
nitrocellulose membranes (LC2000, Invitrogen). Mem-
branes were stained with 0.1% Ponceau S in 5% acetic
acid to confirm proper transfer of proteins. Then, mem-
branes were blocked for 1 hour in 10% milk diluted in
0.05% Tween-20 in PBS (PBS-T). Membranes were incu-
bated overnight at 4°C in primary antibody diluted 1%
BSA/PBS-T. Following incubation with the primary anti-
body, the blot was extensively washed with PBST for 30
minutes and then incubated for 1.5 hours at room tem-
perature with secondary antibody conjugated to HRP
diluted in 1% BSA/PBST. The membrane was then washed
extensively in PBS-T for 30 minutes prior to visualization
using Renaissance™ Chemiluminescence (NEL104, NEN
Life Science, Boston, MA). For stripping antibodies off
western blots, membranes were incubated in stripping
buffer (62.5 mM Tris (pH 6.8), 2% SDS and 100 mM 2-
mercaptoethanol) for 15 minutes in a water bath at 50°C
with shaking. Membranes were washed with PBS-T for 10
minutes and then blocked in 10% milk/PBS-T. COX-2
antibody was diluted 1/200, antibodies from Cell Signal-
ing were diluted in 1/1,000 and HRP-conjugated donkey
rabbit secondary antibody was used at 1/10,000. Images
were obtained and quantified using a UVP imaging sys-
tem with LabWorks software (UVP, Upland, CA).
Flow cytometry
The enriched murine microglia were treated with
cytokines for 24 hours and cells were incubated in
Accutase to detach cells followed by MEM-10C and
scraped. Cells were washed twice with FACS buffer con-
taining Ca2+, Mg+ free PBS, 0.5% BSA and 0.02% sodium
azide. Fc antibody (553142, BD Biosciences, San Jose, CA)
diluted 1/50 was used to block Fc receptors by addition
for 10 minutes on ice. MHC class II antibody conjugated
with FITC (553551, BD Biosciences) diluted 1/25 and
CD40 antibody conjugated with APC (558695, BD Bio-
sciences) diluted 1/100 were incubated with cells for 1
hour on ice in dark. Cells were washed twice and fixed in
1% paraformaldehye. Ten thousand cells were measured
on BD FACSCalibur in the UMDNJ Flow Cytometry Core
Facility (Newark, NJ) using the Cell Quest program. Sam-
ples were prepared in triplicate and geometric mean and
percent positive cells were calculated after correcting for
non-specific binding using cells stained with isotype con-
trol antibodies.
2D-PAGE analysis
After cytokine treatment, cells were thoroughly washed
with 0.5 × PBS and then lysed by sonication in isoelectric
focusing rehydration buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 100 mM DTT, 0.2% Biolytes (pH 5–8), 0.01%
Bromophenol Blue and protease inhibitor). One hundred
micrograms of protein in a total of 185 μL of rehydration
buffer was applied to 11 cm Biorad ReadyStrip IPG Strips
(pH 5–8) for overnight rehydration. First-dimension iso-
electric focusing was carried out on a Biorad PROTEAN
IEF System at the UMDNJ Center for Advanced Proteom-
ics Research http://njms.umdnj.edu/proweb, as described
by the manufacturer for a total focusing time of 75000
VH. The strips were equilibrated with a solution contain-
ing 6 M urea, 0.375 M Tris-HCl, pH 8.8, 2% SDS, 20%
glycerol, 2% (w/v) DTT for 15 min. The strips were further
equilibrated with a solution containing 6 M urea, 0.375 M
Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 2.5% (w/v)
iodoacetamide for 15 min and directly applied to a 12.5%
isocratic SDS-PAGE gel for electrophoresis. The resulting
gel was then fixed (10% Acetic Acid and 40% Ethanol) for
30 min and stained overnight with SYPRO Ruby. Gels
were destained (10% Methanol, 7.5% Acetic Acid) for 60
min. After washing with water, gels were scanned on a
9400 Typhoon Variable Mode Imager (GE Healthcare,
Inc., Piscataway, NJ) using a Green (532) Laser and
610BP30 emission filter. For phospho-specific immunob-
lotting, samples were run in parallel and after the second
dimension; proteins were transferred to nitrocellulose
membranes at 100 V for two hours. Phosphorylated pro-
teins were detected using a Phosphoserine/threonine/
tyrosine antibody using standard western blotting proce-
dures.
Statistical analysis
Data were analyzed using one-way ANOVA followed by
Tukey's post-hoc test or Student's t-test to detect signifi-
cant differences between the means with p < 0.05. Where
the post-hoc test was used for multiple comparisons,
superscript letters indicate significant differences; that is,
means with the same letter are not significantly different.
For example, a bar with the letter a is not statistically dif-
ferent from one with the letters ab, but is different from a
bar with the letter b.
Results
Microglia express CNTF receptor   (CNTFR ), which can be 
induced by IFN
To investigate whether CNTF modulates microglial func-
tions, we first asked whether murine microglia express
receptors for CNTF. The CNTF receptor complex has been
described as the CNTFRα, LIFR and gp130 and microgliaJournal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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are known to express LIFR and gp130 [42]. Therefore, we
assessed expression of CNTFRα proteins. The pro-inflam-
matory cytokine, IFNγ is a strong stimulator for microglia
and it primes microglia for antigen presentation by
increasing expression of a number of cell surface receptors
[2,43]. Therefore, we tested the hypothesis that IFNγ
would upregulate CNTFRα expression in microglia. Pri-
mary microglial cultures were prepared and confirmed to
be greater than 99% homogenous for CD11b. Unstimu-
lated microglia or microglia that were stimulated with
murine IFNγ at 1, 10 and 100 ng/mL for 22 hours were
analyzed. Forty micrograms of total protein lysate were
separated by gel electrophoresis, transblotted to nitrocel-
lulose membranes, probed with CNTFRα antibody and
then probed with β-tubulin antibody to confirm equiva-
lent loading of proteins. These studies revealed that
murine microglia expressed a protein that has a molecular
weight of approximately 50 kDa (similar to that of recom-
binant rat CNTFRα) that reacts with antibodies raised
against recombinant murine CNTFRα (Fig 1). Interest-
ingly, the IFNγ dose response was bell-shaped, with IFNγ
increasing the levels of CNTFRα protein with a maximum
effect seen with 10 ng/mL of IFNγ.
CNTF does not activate STAT and ERK pathways in 
murine microglia
Since murine microglia express the CNTFRα and our pre-
vious studies showed that murine microglia expressed
gp130 as well as the LIF receptor-β (Lin et al., 2008, in
revision for Journal of Neurochemistry), and as CNTF
activates JAK/STAT and Ras/Raf/MAPK pathways in neu-
rons and astrocytes [44,45], we asked whether STAT3 and
ERK would be activated by CNTF. Enriched murine micro-
glial cultures were stimulated with CNTF, CNTF plus
sCNTFRα, IL-6, IL-6 plus sIL-6R or LIF, or left untreated
for twenty minutes (Fig 2A). Ten micrograms of total pro-
tein were analyzed by western blotting for levels of phos-
phorylated STAT3 and ERK. IL-6 alone, IL-6 plus sIL-6R
and LIF increased the phosphorylation of STAT3, most
strongly at tyrosine 705 (tyr705) residue and to a milder
degree at ser727 residue. ERK proteins were also phospho-
rylated in response to IL-6, IL-6 plus sIL-6R and LIF stim-
ulation. In distinct contrast, neither CNTF nor the
combination of CNTF and sCNTFRα increased phosphor-
ylation of STAT3 or ERK.
Since recombinant murine CNTF is not commercially
available, recombinant rat CNTF (rrCNTF) was used in
our experiments. To confirm that rrCNTF binds to murine
CNTFRα to activate JAK/STAT pathways, enriched murine
astrocyte cultures were stimulated with rrCNTF and rmIL-
6 for twenty minutes and STAT3 phosphorylation was
assessed. Both rrCNTF and rmIL-6 increased phosphoryla-
tion of STAT3 in murine astrocytes (Fig 2B). To confirm
that CNTF does not activate STAT3 in microglia, we also
stimulated enriched rat microglial cultures with rrCNTF
and rrIL-6 for twenty minutes and examined STAT3 phos-
phorylation. Again, rrCNTF failed to induce STAT3 phos-
phorylation in rat microglia while IL-6 stimulated strong
phosphorylation of STAT3 tyr705 (Fig 2C). To determine
whether the failure of CNTF to phosphorylate STAT3 was
due to a slower recruitment of the receptors, we stimu-
lated murine microglia with rrCNTF for 2, 5, 20, 40 and
60 minutes or rmIL-6 for 20 minutes. rrCNTF did not
increase STAT3 phosphorylation at any time point exam-
ined whereas rmIL-6 stimulation strongly increased
STAT3 phosphorylation compared to untreated cells (Fig
2D).
CNTF treatment results in protein phosphorylation and 
dephosphorylation in murine microglia
To confirm that CNTF is altering intracellular signaling
pathways in murine microglia, despite the fact that we did
not see increased phosphorylation of STAT-3 or ERK, we
performed 2D gel electrophoresis followed by western
blot analysis for tyrosine/serine/threonine phosphoryla-
tion. Murine microglia were stimulated with CNTF (10
ng/mL) for 20 minutes or left untreated. One hundred
micrograms of protein lysates were separated by electro-
phoresis on each gel and duplicated gels were generated.
One gel from each condition was stained with SYPRO
Ruby or used for phospho-protein analysis where proteins
were transferred to nitrocellulose membranes. SYPRO
Ruby staining revealed hundreds of proteins of varying
molecular weights and isoelectric points (pI) (Fig 3A, B).
Western blot analyses showed that CNTF altered the phos-
phorylation of several proteins. For instance, the intensity
of spot 1 was greater in CNTF treated cells (Fig 3D, F), cor-
responding to spot 1' (Fig 3C, E) in untreated cells, which
indicated increased phosphorylation subsequent to CNTF
stimulation. Spots 2a, 2b and 2c (Fig 3D, F), correspond-
ing to Spot 2a', 2b' and 2c' (Fig 3C, E), respectively, also
appeared more abundant in CNTF treated samples, indi-
cating increased phosphorylation. Spot 3a and 3b (Fig
3D, F), corresponding to spots 3a' and 3b' (Fig 3C, E),
showed a dramatic decrease in signal, indicating that
phosphorylation of the protein was greatly reduced by
CNTF treatment (Fig 3C–F). Finally, CNTF increased
phosphorylation of Spot 4 (Fig 3D, F), corresponding to
Spot 4' in the control cells (Fig 3C, E). Mass spectral anal-
yses established that Spot 1 is the hemopoietic cell specific
Lyn substrate-1 (gi:13938627) and Spots 2a, 2b and 2c are
forms of β-tubulin 5 (gi:7106439). Spots 3 and 4 were too
low in quantity to be identified.
CNTF in combination with sCNTFR  induces 
cyclooxygenase-2 (Cox-2) and prostaglandin E2 (PGE2) in 
microglia that is gp130-independent
Cox-2 is an inducible cyclooxygenase and is rapidly
expressed by microglia in response to a variety of stimuli,Journal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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and PGE2 is one of the metabolites produced by Cox-2.
Therefore, the production of Cox-2 and PGE2 were exam-
ined after stimulating microglia with CNTF alone or in
combination with sCNTFRα. Murine microglia were
treated with CNTF (10 ng/mL), the combination of CNTF
(10 ng/mL) and sCNTFRα (200 ng/mL) or sCNTFRα (200
ng/mL), or left untreated for 16–18 hours. Ten micro-
grams of total protein were analyzed by western blotting
for Cox-2 expression. The murine microglia in these stud-
ies had low basal expression of Cox-2 as would be
expected. The combination of CNTF and sCNTFRα
increased Cox-2 expression approximately 2 fold. By con-
trast, neither CNTFR nor sCNTFRα alone had any effect
(Fig 4A). After microglia were treated with CNTF and
sCNTFRα for 16 hours, the supernatants were collected
and analyzed for PGE2  content. PGE2  secretion was
increased 1.7 fold (p < 0.05) by the combination of CNTF
and sCNTFRα compared to untreated cells (Fig 4B).
Microglia were stimulated with 0, 0.4, 2, 10, 25 or 50 ng/
mL of CNTF with sCNTFRα (200 ng/mL), or stimulated
with LPS at 0.1 ng/mL for 16–18 hours, and Cox-2 protein
expression was analyzed by western blotting. Microglial
production of Cox-2 in response to CNTF was dose
dependent with the maximum effect seen at 2 ng/mL of
CNTF. Thus, the ED50 for this induction is around 0.2 ng/
mL (Fig 4C). Compared to LPS CNTF/sCNTFRα is a weak
inducer of Cox-2 in that CNTF at 2 ng/mL plus sCNTFRα
at 200 ng/mL increased Cox-2 by 1.6 fold while LPS at 0.1
ng/mL increased Cox-2 by 54 fold.
CNTF is a member of the IL-6 family of cytokines, which
share gp130 as a common signaling molecule. To deter-
mine whether Cox-2 induction by CNTF/sCNTFRα
requires gp130, we treated microglia with neutralizing
antibodies against murine gp130 (5 μg/mL, about 10
times of ND50 based on manufacturer's information), the
combination of CNTF (10 ng/mL) and sCNTFRα (200 ng/
mL), or gp130 antibody (5 μg/mL) for 1 h followed by
stimulation of CNTF (10 ng/mL)/sCNTFRα (200 ng/mL)
for 16–18 hrs. In these experiments, neutralizing gp130
activity promoted Cox-2 expression by 2.5 fold compared
to unstimulated cells (Fig 4D). CNTF/sCNTFRα induced
Cox-2 by two fold compared to untreated cells. Unexpect-
edly, administering CNTF/sCNTFRα with gp130 antibod-
ies further induced Cox-2 by two fold compared to
stimulating with gp130 antibody alone. To confirm that
the antibody blocks gp130 activity, we stimulated micro-
glia with gp130 antibody (5 μg/mL), IL-6 (5 ng/mL), a
combination of IL-6 (5 ng/mL) and soluble IL-6R (200
ng/mL), gp130 antibody for 1 hour followed by IL-6 (5
ng/mL) or a combination of IL-6 (5 ng/mL) and soluble
IL-6R (200 ng/mL), or left cells untreated (UT) for 20 min-
utes. Western blot analysis of STAT3 phosphorylation
showed that the gp130 antibody completely blocked IL-6-
induced STAT3 phosphorylation as expected (Fig 4E).
CNTF in combination with sCNTFR  potentiates the effect 
of IFN  on CD40, but not MHC class II, expression in 
murine microglia
Antigen presenting and co-stimulatory molecule expres-
sion is required for microglia to induce T cell responses.
Therefore, we tested the hypothesis that CNTF would reg-
ulate microglial expression of MHC class II and CD40.
Enriched murine microglial cultures were stimulated with
IFNγ alone, IFNγ plus CNTF or IFNγ plus the combination
of CNTF and sCNTFRα, or cells were left untreated for
twenty-four hours. Flow cytometry analysis showed that
IFNγ strongly upregulated surface expression of CD40 on
microglia and more than 90% of the cells were positive for
CD40 (Fig 5). Stimulating with IFN plus CNTF showed a
trend of increased CD40 expression compared to IFNγ
alone, and an increase of approximately 10% in the mean
fluorescence intensity (MFI). Interestingly, the combina-
tion of CNTF and sCNTFRα collaborated with IFNγ to
increase CD40 expression by approximately 30% com-
pared to IFNγ alone. On the other hand, IFNγ treatment
increased MHC class II levels on microglia and approxi-
Murine microglia express CNTFRα, which is induced further  by IFNγ Figure 1
Murine microglia express CNTFRα, which is induced 
further by IFNγ. Panel A shows a representative photo-
graph of cultured murine microglia. Panel B shows repre-
sentative western blots for CNTFRα proteins in murine 
microglial cultures induced by IFNγ. Microglia were treated 
with IFNγ 1, 10 and 100 ng/mL, or left untouched for 22 
hours. Forty micrograms of protein lysates were analyzed by 
western blotting. Membranes were probed with CNTFRα 
antibody and were re-probed with β-tubulin antibody to con-
firm equivalent protein loading. Recombinant rat soluble 
CNTFRα was loaded as a positive control (leftmost lane).Journal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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mately 60% of the cells were positive for MHC class II.
However, combinatorial treatment with IFNγ and CNTF
had no effect on MHC class II levels, neither MFI nor
%MHC class II+, and adding sCNTFRα was no more effec-
tive.
CNTF in the presence of sCNTFR  potentiates the effect of 
IFN  on CD40, but not MHC class II, expression in 
dendritic-like microglia
Granulocyte-macrophage colony stimulating factor
(GMCSF) transforms microglia into dendritic-like cells
[46]. Using CD11c as a dendritic cell marker, we estab-
lished that stimulating murine microglia with GMCSF (10
ng/mL) for eight days resulted in 80% of these cells
expressing CD11c. Using this culture paradigm, we tested
the hypothesis that the combination of CNTF and sCNT-
FRα would also induce CD40 expression in dendritic-like
cells. Microglia were treated with GMCSF for seven days
and then stimulated with CNTF alone, CNTF plus sCNT-
FRα, IFNγ, IFNγ plus CNTF or IFNγ plus CNTF and sCNT-
FRα, or left untreated for twenty-four hours. By flow
cytometry analyses, IFNγ increased CD40 expression in
these dendritic-like cells, and the combination of CNTF
and sCNTFRα, but not CNTF alone, collaborated with
IFNγ to double CD40 expression as compared to IFNγ
alone as measured by MFI and %CD40+ (Fig 6). IFNγ
induced MHC class II in these cells, but neither CNTF nor
the combination of CNTF and sCNTFRα further increased
class II expression. In the absence of IFNγ, neither CNTF
alone nor the combination of CNTF with sCNTFRα
altered the levels of CD40 or MHC class II compared to
untreated cells.
Discussion
Studies on immunoreactivity for CNTFRα have shown
that CNTFRα is most highly expressed by neurons and
expressed by a subset of astrocytes [47-49]. Consistent
with previous studies on rat microglia [39], here we show
that murine microglia also express CNTFRα. The analyses
reported herein further reveal that 1) the combination of
CNTF and sCNTFRα, but neither alone, induces Cox-2
expression and PGE2 secretion from microglia; 2) Neutral-
izing antibodies against gp130 fail to inhibit CNTF/sCNT-
FRα-induced Cox-2, and neither CNTF nor CNTF/
sCNTFRα activates canonical IL-6 signal transducers,
including STAT3 and ERK; 3) CNTF increases the phos-
phorylation of the Lyn substrate-1 and β-tubulin 5; 4) The
combination of CNTF and sCNTFRα collaborate with
IFNγ to promote CD40, but not MHC class II, expression
in microglia and especially in dendritic-like cells. Cumu-
latively, these data suggest that CNTF in combination with
sCNTFRα serves as a weak pro-inflammatory signal to
enhance the production of Cox-2, PGE2 and CD40 in
microglia.
Our studies on murine microglia show that in the pres-
ence of soluble CNTFRα, CNTF increases Cox-2 produc-
tion in a dose-dependent manner. Secretion of PGE2, as
one of the metabolites produced by Cox-2 from microglia
is also increased following CNTF/sCNTFRα stimulation.
By contrast, Shapiro et al. showed that in human blood
mononuclear cells, the combination of CNTF at 3 μg/mL
and sCNTFRα suppressed PGE2  production and IL-6
showed similar inhibitory effects in their studies [50].
One explanation for this difference in response is that
microglia are not simply macrophages that are residing
within the CNS. Additionally, since human CNTF, at high
concentrations (beyond 50 ng/mL), can bind to IL-6R and
induces STAT3 activation [51] the inhibitory effect seen in
the human mononuclear cells with CNTF may be a result
of activating IL-6R. CNTF at nanogram doses does not
activate STAT3, which suggests that it does not bind to IL-
6R. Therefore, our studies indicate that in murine micro-
glia, CNTF in combination with sCNTFRα promotes Cox-
2 and PGE2 production.
The majority of studies to date indicate that CNTF binds
to its specific CNTFRα to recruit LIFR and gp130, which
leads to activation of JAK/STAT and Ras/Raf/MAPK path-
CNTF does not activate STAT or ERK pathways in murine  microglia Figure 2
CNTF does not activate STAT or ERK pathways in 
murine microglia. After cytokine treatment, ten micro-
grams of protein lysates were analyzed by western blotting 
for phosphorylated proteins and the membranes were 
striped and reprobed with antibody against total protein. A, 
Enriched murine microglial cultures were treated with CNTF 
(10 ng/mL), IL-6 (5 ng/mL), LIF (10 ng/mL), CNTF (10 ng/mL) 
plus soluble CNTFRα (200 ng/mL), IL-6 (5 ng/mL) plus solu-
ble IL-6R (200 ng/mL), or left untouched (UT) for 20 min-
utes. B, Murine astrocytes were treated with CNTF (10 ng/
mL) or IL-6 (5 ng/mL) or left untreated for 20 minutes. C, 
Enriched rat microglial cultures (purity > 99%) were treated 
with CNTF (10 ng/mL) or IL-6 (10 ng/mL) or left untreated 
for 20 minutes. D, Murine microglia were treated with 
CNTF (10 ng/mL) for 2, 5, 20, 40 and 60 minutes or IL-6 (5 
ng/mL) or left untreated for 20 minutes. Data are represent-
ative of 3 independent experiments.Journal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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CNTF treatment results in protein phosphorylation and dephosphorylation in murine microglia Figure 3
CNTF treatment results in protein phosphorylation and dephosphorylation in murine microglia. Enriched 
murine microglia were treated with CNTF (10 ng/mL) for 20 minutes or left untreated. One hundred micrograms of protein 
lysate were separated by isoelectrofocusing and subsequent SDS/PAGE under reducing conditions. Gels were fixed, stained 
with SYPRO Ruby, destained and then scanned on a 9410 Typhoon Imager. Panel A shows SYPRO Ruby staining of untreated 
microglia, and Panel B shows SYPRO Ruby staining of CNTF-stimulated microglia. For phosphospecific-immunoblotting, dupli-
cate gels were transferred to nitrocellulose membranes and probed with an antibody against phospho-tyrsoine/serine/threo-
nine to detect phosphorylated proteins in both untreated (C) and CNTF-stimulated microglia (D). Spots which showed 
altered phosphorylation are depicted at higher power for untreated (E) and CNTF stimulated microglia (F). CNTF altered 
phosphorylation of several proteins. Mass spectral analyses identified that Spot 1 is the hemopoietic cell specific Lyn substrate-
1 (gi:13938627) and Spots 2a, 2b and 2c are β-tubulin 5 (gi:7106439). Spots 3 and 4 were too low in quantity to be unidentified. 
Data are representative of 3 independent experiments.Journal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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ways [40,44,45]. There is evidence that LIFR and IL-6R can
also serve as α-receptors for CNTF [51-53]. Intriguingly,
our studies on microglia strongly suggest that CNTF con-
veys its signal independent of gp130. It has been shown
that p38MAPK mediates the LPS induced Cox-2 expres-
sion in microglia [54,55]. However, we did not observe
evident phosphorylation of p38MAPK after stimulating
murine microglia with CNTF (10 ng/mL)/sCNTFRα (200
ng/mL) for 20 minutes, while LPS (10 ng/mL) induced
strong phosphorylation of p38MAPK (data not shown).
Thus, it is unlikely, that our results are due to endotoxin
contamination of the recombinant CNTF we utilized.
Nevertheless, LPS is a much stronger inducer of Cox-2
than CNTF/sCNTFRα and thus, it may be that the CNTF/
sCNTFRα induced p38MAPK phosphorylation is too low
to be detected. Alternatively, it is possible that CNTF/
sCNTFRα acts indirectly to induce Cox-2 via phospholi-
pase A2 [56].
CNTF has previously been shown to exert pro-inflamma-
tory actions. For instance, intravenous injections of CNTF
induce acute-phase responses with increased expression
of  β-fibrinogen,  α-1-antichymotrypsin and α-2-mac-
roglobulin in rat liver cells [35,36]. CNTFRα is GPI-linked
to cell membranes and is released from skeletal muscles
after nerve injury, and the concentration of sCNTFRα is
elevated in the CSF of patients with lupus, ALS and epi-
lepsy [57,58]. These data suggest that sCNTFRα is an
injury-induced signal and is involved in central and
peripheral responses to injury. It has been shown that
sCNTFRα alone or in combination with CNTF can serve as
a chemoattractant for macrophages [59]. Thus, our results
were not completely unexpected.
Although the conventional view of sCNTFRα is that it
conveys signals of CNTF for cells that do not express CNT-
FRα [58], a recent study revealed that a complex formed
between CNTF and sCNTFRα promotes neurite out-
growth and regulates expression of several neurotrophic
genes on neurons, whereas CNTF alone was without effect
[60]. In agreement with this study, our studies show that
although microglia respond to CNTF, the complex formed
by CNTF and sCNTFRα effectively promotes Cox-2, PGE2
and CD40 production in microglia whereas CNTF alone is
with little effect. Interestingly, the effect of CNTF and
sCNTFRα was more pronounced in the dendritic-like
microglia than in the microglial cultures, which suggests
that dendritic-like microglia respond more strongly to
CNTF/sCNTFRα. Whereas, exogenous CNTF administra-
tion has been shown to exert protective effects in MS and
EAE, our data and those of others would caution against
the use of CNTF as a neuroprotective agent in that the
inflammatory side effects subsequent to delivery may
limit the clinical usefulness of administering CNTF in
treating neurodegenerative diseases, especially where
there is an inflammatory component.
The combination of CNTF and soluble CNTFRα increases  Cox-2 and PGE2 production in murine microglia that is not  inhibited by a gp130 function blocking antibody Figure 4
The combination of CNTF and soluble CNTFRα 
increases Cox-2 and PGE2 production in murine 
microglia that is not inhibited by a gp130 function 
blocking antibody. After cytokine treatment, cultured 
murine microglia were collected and 10 micrograms of pro-
tein lysates were analyzed by western blotting. A, Murine 
microglia cultures were treated with CNTF (10 ng/mL) 
(CN), the combination of CNTF (10 ng/mL) and soluble 
CNTFRα (200 ng/mL) (CN+sR), soluble CNTFRα (200 ng/
mL) (sR), or left untouched (UT) for 16–18 hours. Mem-
branes were probed with Cox-2 antibody and reprobed with 
β-tubulin antibody to confirm equivalent protein loading. 
Data are representative of 3 independent experiments. B, 
Murine microglia were treated with the combination of 
CNTF (5 ng/mL) and soluble CNTFRα (200 ng/mL) (CN+sR) 
or left untouched (UT) for 16–18 h. Supernatants were col-
lected and analyzed by PGE2 ELISA. Values represent the 
means ± S.E.M. from 4 independent experiments. *p < 0.05 
by Student's t-test. C, Murine microglia were treated with 
CNTF 0.4, 2, 10, 25 and 50 ng/mL in combination with solu-
ble CNTFRα (200 ng/mL), or with LPS 0.1 ng/mL for 16–18 
hours. Membranes were probed with Cox-2 antibody and 
reprobed with β-tubulin antibody. Data are representative of 
two independent experiments. D, Microglia were treated 
with gp130 antibody (5 μg/mL) (ab), the combination of 
CNTF (10 ng/mL) and soluble CNTFRα (200 ng/mL) 
(CN+sR), gp130 antibody for 1 hour followed by the combi-
nation of CNTF (10 ng/mL) and soluble CNTFRα (200 ng/
mL) (ab+CN+sR), or left untreated (UT) for 18 h. Mem-
branes were probed with Cox-2 antibody and reprobed with 
β-tubulin antibody. Data are representative of 4 independent 
experiments. E, Microglia were treated with gp130 antibody 
(5 μg/mL) (ab), IL-6 (5 ng/mL), a combination of IL-6 (5 ng/
mL) and soluble IL-6R (200 ng/mL) (IL-6+sR), gp130 antibody 
for 1 hour followed by IL-6 (5 ng/mL) (ab+IL-6) or a combi-
nation of IL-6 (5 ng/mL) and soluble IL-6R (200 ng/mL) 
(ab+IL-6+sR), or left untreated (UT) for 20 minutes. Mem-
branes were probed with phospho-STAT3 tyr705 antibody, 
stripped, and re-probed with STAT3 antibody.Journal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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Our data show that CNTF does not activate STAT3 and
ERK pathways in microglia. In contrast, Krady et al. (2008)
showed that rrCNTF elicits a modest increase in STAT3
phosphorylation in rat microglia [39]. Initially we sur-
mised that the difference in responsiveness was species
related, however, subsequent to careful analyses the dis-
crepancy between those data and the data reported herein
can be attributed to differences in the purity of the micro-
glial cultures. Rat microglial cultures are typically enriched
by incubating non-adherent cells obtained from mixed
glial cultures on bacteriological dishes. Incubating rat
CNTF in combination with sCNTFRα potentiates the effect  of IFNγ on CD40, but not MHC class II, expression in murine  microglia Figure 5
CNTF in combination with sCNTFRα potentiates the 
effect of IFNγ on CD40, but not MHC class II, expres-
sion in murine microglia. Microglia were treated with 
IFNγ (10 ng/mL) (IFN), IFNγ (10 ng/mL) plus CNTF (10 ng/
mL) (IFN+CN), or IFNγ (10 ng/mL) plus the combination of 
CNTF (10 ng/mL) and sCNTFRα (200 ng/mL) (IFN+CN+R), 
or left untreated (UT) for 24 hours. 10,000 cells were ana-
lyzed by flow cytometry for CD40 and MHC class II expres-
sion. Panel A shows representative histograms for CD40 
(APC) while Panel B shows representative histograms for 
MHC class II (FITC). C, Mean fluorescence of CD40 and 
inset shows averaged values from three independent experi-
ments as normalized to IFNγ alone. D, Mean fluorescence of 
MHC class II; E, Percentage of CD40 positive cells; F, Per-
centage of MHC class II positive cells. Values represent the 
means ± S.E.M. from triplicates in one experiment. Different 
superscript letters indicate significant differences at the p < 
0.05 levels as analyzed by one-way ANOVA followed by 
Tukey's post-hoc test. Data are representative of 3 inde-
pendent experiments.
CNTF in the presence of sCNTFRα potentiates the effect of  IFNγ on CD40, but not MHC class II, expression in dendritic- like microglia Figure 6
CNTF in the presence of sCNTFRα potentiates the 
effect of IFNγ on CD40, but not MHC class II, expres-
sion in dendritic-like microglia. After continuous growth 
in GMCSF (10 ng/mL) for 7 days, the dendritic-like microglia 
were treated with CNTF (10 ng/mL) (CN), a combination of 
CNTF (10 ng/mL) and sCNTFRα (200 ng/mL) (CN+R), IFNγ 
(10 ng/mL) (IFN), IFNγ (10 ng/mL) plus CNTF (10 ng/mL) 
(IFN+CN) or IFNγ (10 ng/mL) plus the combination of CNTF 
(10 ng/mL) and sCNTFRα (200 ng/mL) (IFN+CN+R) or left 
untreated (UT) for 24 hours. 10,000 cells were analyzed by 
flow cytometry for CD40 and MHC class II expression. Panel 
A and C show representative histograms for CD40 expres-
sion while Panel B and D show representative histograms for 
MHC class II expression. E, Mean fluorescence of CD40; 
inset shows data from three independent experiments, IFNγ, 
IFNγ plus the combination of CNTF and sCNTFRα. F, Mean 
fluorescence of MHC class II; G, Percentage of CD40 posi-
tive cells and inset shows data from three independent 
experiments. H, Percentage of MHC class II positive cells. 
Values represent the means ± S.E.M. from triplicates in one 
experiment. Different superscript letters indicate significant 
differences at the p < 0.05 levels as analyzed by one-way 
ANOVA followed by Tukey's post-hoc test. Data are repre-
sentative of 3 independent experiments.Journal of Neuroinflammation 2009, 6:7 http://www.jneuroinflammation.com/content/6/1/7
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microglia on bacteriological dishes for 10 minutes (our
protocol) instead of 40 minutes (previous protocol)
increases the purity of the microglial cultures from 90% to
99% as determined by CD11b and A2B5 staining. In these
highly enriched rat microglial cultures STAT3 is not phos-
phorylated following CNTF treatment whereas in the less
enriched microglial cultures CNTF induces STAT3 phos-
phorylation. This STAT3 signaling likely results from acti-
vation with the contaminating oligodendrocyte
progenitors (OPCs) and, to a smaller degree, astrocytes.
We also assessed whether soluble factors secreted from
OPCs and/or astrocytes promote microglial STAT3 phos-
phorylation in response to CNTF. To do so, highly
enriched rat microglia were cultured in oligodendrocyte
or astrocyte-conditioned media overnight followed by
CNTF treatment for 20 minutes. As expected, CNTF failed
to elicit STAT3 phosphorylation whether exposed to OPC
or astrocyte-conditioned medium (unpublished data).
Altogether, our studies demonstrate that CNTF does not
elicit STAT3 phosphorylation in either rat or murine
microglia, much to our surprise.
In summary, although CNTF is known for its trophic
effects on neurons and oligodendrocytes, it also regulates
neuroinflammation. Our results shed light on how CNTF
in combination with its soluble receptor serves as a pro-
inflammatory signal to enhance central and peripheral
immune responses. In particular, our data show that
CNTF serves as a weak pro-inflammatory signal to
enhance the production of Cox-2, PGE2 and CD40 in
microglia. CNTF was evaluated in clinical trials, which
were halted due to unexpected side effects. Our results
provide new data and new insights into possible compli-
cations of utilizing CNTF as a therapeutic treatment for
motor neuron diseases. In particular, in addition to the
weight loss that has been documented [61-63]. CNTF
treatment could raise central and peripheral immune
responses and lead to a more inflamed environment,
which may counteract its trophic activity on neurons and
oligodendrocytes.
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